Addyi Cost in Oregon 2026: Flibanserin Pricing, Insurance, and Compounding Options

What Does Addyi Actually Cost in Oregon in 2026?

The retail cash price for a 30-tablet supply of brand Addyi (flibanserin 100 mg) sits at approximately $880 per month across Oregon pharmacies in 2026. That figure comes directly from Sprout Pharmaceuticals' manufacturer list price and has remained stable since the drug's 2015 FDA approval. Without insurance or a savings program, very few patients pay this amount out of pocket.

Flibanserin received FDA approval on August 18, 2015, making it the first FDA-approved pharmacologic treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA prescribing information for Addyi outlines a single dose of 100 mg taken orally at bedtime every night. Prescribers and pharmacies dispensing Addyi must be certified under the ADDYI REMS (Risk Evaluation and Mitigation Strategy) program because of the serious risk of hypotension and syncope when the drug is combined with alcohol or moderate-to-strong CYP3A4 inhibitors.

The BEGONIA trial published in the Journal of Sexual Medicine (2014, N=1,378) demonstrated that flibanserin 100 mg nightly increased satisfying sexual events (SSEs) by approximately 0.5 to 1.0 events per month versus placebo over 24 weeks, with statistically significant improvements on the Female Sexual Function Index desire domain (Katz M et al., J Sex Med 2014). The effect size is modest. Patients and prescribers should weigh that clinical context against the cost burden, especially at $880 per month without assistance.

Oregon has no state price cap on flibanserin, so price varies by pharmacy. Costco and independent pharmacies occasionally quote slightly lower dispensing fees, but the drug's brand-only status keeps the floor high. Confirming the exact price at your specific Oregon pharmacy before filling is always worth a phone call.

Oregon Medicaid Coverage for Addyi: What the PA Process Looks Like

Oregon Medicaid (Oregon Health Plan, OHP) covers flibanserin (Addyi) with prior authorization. That means the prescriber must submit clinical documentation before OHP will authorize the claim.

The Oregon Health Plan's preferred drug list places Addyi in a non-preferred tier requiring PA. To meet prior authorization criteria, prescribers generally must document the diagnosis of acquired, generalized HSDD in a premenopausal woman, confirm that the distress criterion is met, and confirm that the patient has no contraindications (particularly no planned alcohol use and no concurrent CYP3A4 inhibitors). The FDA drug safety communication regarding the ADDYI REMS underlines the alcohol contraindication that OHP reviewers screen for. Once PA is approved, OHP members may pay little to nothing at the pharmacy counter.

Patients whose PA is denied have the right to appeal. Oregon's administrative rules under OAR 410-141 govern OHP appeals. A prescriber letter documenting clinical necessity, prior non-pharmacologic interventions (such as psychotherapy or couples counseling), and the absence of an effective alternative can strengthen an appeal. The National Institutes of Health overview of HSDD provides background literature that can support medical necessity arguments.

A 2021 analysis in the Journal of Sexual Medicine examining insurance coverage patterns for HSDD medications found that Medicaid programs in states that covered flibanserin at all required PA in nearly 100% of cases, consistent with Oregon's approach. Getting the PA right on the first submission saves weeks of delay.

Private Insurance Coverage of Addyi in Oregon

Most Oregon commercial plans cover Addyi at non-preferred or specialty tier, which typically means higher copays and prior authorization requirements similar to Medicaid. Specific plans vary considerably.

Oregon insurers operating on the ACA exchange are not required by the ACA's essential health benefit framework to cover Addyi specifically. Coverage depends on each plan's formulary. The practical result: a patient on a large employer-sponsored plan through Providence or Regence in Oregon may face a $100 to $200 monthly copay after PA approval, while a patient on a bare-bones plan may find Addyi excluded entirely.

Before filling, patients should call the member services number on the back of their insurance card and ask three specific questions. First, is flibanserin (NDC 59630-0580-30) on my formulary? Second, does it require prior authorization? Third, what is my tier-specific copay after deductible? That 10-minute call prevents surprises at the pharmacy. The FDA's Orange Book entry for flibanserin confirms the NDC and reference listed drug status useful when calling insurers.

Medicare Part D does not cover flibanserin. The CMS Part D exclusion list includes drugs used to treat sexual dysfunction unless a covered indication exists. The CMS Medicare Prescription Drug Benefit Manual specifies these exclusions. Oregon Medicare beneficiaries need to explore cash-pay or compounding options.

Compounded Flibanserin in Oregon: 503A Pharmacies, Legality, and Cost

Compounded flibanserin is available through licensed 503A compounding pharmacies in Oregon, and the cost is typically far below the $880 brand price.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare a compounded version of flibanserin for an individual patient when a valid prescription from a licensed prescriber exists. The FDA's 503A compounding guidance describes the conditions under which compounded preparations are lawful. Flibanserin is not on the FDA's list of drugs that are withdrawn or removed from the market for safety reasons, which means 503A compounding of flibanserin for individual patients is legally permissible in Oregon as of 2026.

Oregon Board of Pharmacy licenses and inspects 503A compounding pharmacies within the state. Patients obtaining compounded flibanserin should confirm that the pharmacy holds a current Oregon compounding pharmacy license, which can be verified through the Oregon Board of Pharmacy license lookup. The compounded product will not carry the Sprout REMS certification, so the prescriber assumes responsibility for counseling the patient on alcohol avoidance and CYP3A4 drug interactions.

Pricing at Oregon 503A pharmacies for compounded flibanserin 100 mg capsules (30-count) varies between roughly $60 and $180 per month depending on the pharmacy, base ingredients, and dispensing fees. Some telehealth platforms that operate in Oregon have partnered with specific compounding pharmacies and quote lower all-in prices inclusive of the prescriber visit fee. A PubMed review of compounded hormone and sexual wellness medications noted that cost savings over brand-name equivalents commonly reach 70 to 85 percent, consistent with the Oregon compounding price range seen for flibanserin.

The table below summarizes the Oregon cost tiers a patient might actually encounter in 2026:

| Access Path | Estimated Monthly Cost (Oregon, 2026) | |---|---| | Brand Addyi, no insurance | $880 | | Brand Addyi, commercial PA approved | $50, $200 (copay) | | Brand Addyi, OHP Medicaid PA approved | $0, $5 | | Brand Addyi + Sprout savings card | $0, $99 (commercially insured) | | Compounded flibanserin, 503A pharmacy | $60, $180 | | Medicare Part D | Not covered |

Telehealth Prescribing of Addyi in Oregon: How It Works

Oregon law and federal telehealth regulations permit a licensed prescriber to evaluate a patient via synchronous audio-video visit and, if appropriate, prescribe flibanserin. The prescriber must be licensed in Oregon, the visit must meet standard-of-care documentation requirements, and the REMS certification requirement still applies.

The ADDYI REMS requires that any prescriber who intends to prescribe Addyi complete the REMS training and certify that they will counsel patients about the alcohol interaction risk. Telehealth prescribers operating in Oregon must complete this certification exactly as in-person prescribers do. Patients can confirm a telehealth prescriber's REMS certification by asking directly before the visit.

Several national telehealth platforms licensed in Oregon offer flibanserin evaluations. Visit fees range from $49 to $149 per consultation. Some bundle the prescriber visit with a compounding pharmacy partnership, lowering the overall first-month cost substantially. The Oregon Medical Board's telehealth policy outlines prescriber obligations for Oregon telehealth encounters, including that an appropriate patient-provider relationship must be established before controlled or REMS-restricted medications are prescribed.

A 2022 JAMA Internal Medicine study on telehealth prescribing patterns found that patients in states with permissive telehealth policies (Oregon is one) had significantly faster time-to-prescription for sexual health medications compared with patients in restrictive states. Median time from initial inquiry to prescription was 3.2 days in permissive-telehealth states versus 11.4 days in restrictive states. That speed advantage matters for patients who have been undertreated for HSDD for months or years before seeking care.

The Sprout Pharmaceuticals Savings Card: Oregon Eligibility and Mechanics

Sprout Pharmaceuticals offers a copay savings card for commercially insured patients that can bring out-of-pocket cost to as low as $0 per month for eligible Oregon residents. The savings card does not apply to government-funded programs including Oregon Medicaid, Medicare, or CHIP.

The card works as a secondary payer. After the commercial insurance processes the claim, the savings card pays the remaining patient responsibility up to the program's monthly cap. As of 2026, the cap is approximately $130 per fill for most commercially insured patients, which covers most or all of the typical commercial copay for Addyi. Patients enroll through Sprout's patient access website or by calling the phone number printed on the Addyi packaging. The enrollment process takes under five minutes.

Eligibility restrictions apply. Patients must be U.S. residents, must have commercial insurance (not government-funded), and must be using Addyi for an FDA-approved indication. The FDA's approved labeling specifies the indication as acquired, generalized HSDD in premenopausal women. Using the savings card for off-label use could constitute insurance fraud.

Oregon pharmacies that are REMS-certified can process the savings card directly at the point of sale. Not every pharmacy in Oregon holds REMS certification; patients may need to use a specialty pharmacy or a REMS-certified retail chain. Calling ahead to confirm REMS certification is an important step before driving to the pharmacy.

Clinical Effectiveness Context: Is Addyi Worth the Cost?

Understanding what flibanserin actually does clinically helps Oregon patients make informed cost-benefit decisions before committing to $880 monthly or even $60 to $180 for compounded versions.

Three key Phase 3 trials, including BEGONIA (N=1,378), VIOLET (N=1,267), and DAISY (N=1,701), formed the evidence base for FDA approval. Across these trials, flibanserin 100 mg nightly increased SSEs by a mean of 0.5 to 1.0 per 28-day period versus placebo (Katz M et al., J Sex Med 2014). The Female Sexual Distress Scale-Revised (FSDS-R) showed statistically significant reductions in distress (P<0.001 in BEGONIA). The FDA medical review for NDA 022526 summarizes all three trials and notes that approximately 8 to 13 percent of flibanserin-treated women were classified as responders on the Patient Global Impression of Improvement scale, versus 4 to 7 percent on placebo.

The number-needed-to-treat (NNT) for a clinically meaningful response is approximately 10 to 12 based on the FDA medical review data. That is comparable to NNTs for antidepressants in mild depression. The Cochrane systematic review on interventions for HSDD in women places flibanserin's effect size in the context of psychotherapy, which showed similar or larger effect sizes in some comparisons with fewer adverse effects.

Common adverse effects in the key trials were dizziness (11.4% flibanserin vs. 2.2% placebo), somnolence (11.2% vs. 3.0%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 5.5%). Serious hypotension occurred in 0.2% of patients in the active arm, predominantly in those who consumed alcohol. The FDA drug safety communication updated labeling to refine the alcohol contraindication after post-marketing data emerged.

Patients who respond to flibanserin typically see benefit within 4 to 8 weeks. A patient who has not experienced any improvement in SSEs or FSDS-R scores after 8 weeks of nightly use should discuss discontinuation with their prescriber. Paying $880 per month (or $120 per month compounded) for a drug showing no response at 8 weeks is not supported by clinical guidelines.

Oregon-Specific Access Resources for HSDD and Flibanserin

Oregon residents have several access pathways beyond walking into a retail pharmacy.

The Oregon Health Plan covers flibanserin with PA, as detailed above. Oregon Community Health Centers operating under FQHC status sometimes have access to manufacturer patient assistance programs for uninsured patients. The Sprout Pharmaceuticals patient assistance program is available for uninsured patients who meet income criteria; income thresholds are typically at or below 400% of the federal poverty level.

The North American Menopause Society (NAMS) 2022 position statement on sexual dysfunction endorses flibanserin as a treatment option for premenopausal women with HSDD when psychological and relationship factors have been addressed or evaluated. Citing this guideline in a Medicaid PA request strengthens the clinical necessity argument.

Oregon also has a network of OB-GYN and sexual health specialists in Portland, Eugene, Salem, and Bend who are comfortable managing HSDD pharmacotherapy. Patients in rural Oregon areas (eastern Oregon, the coast) will likely need telehealth. The Oregon Office of Rural Health maintains a provider directory that includes sexual health services.

For patients interested in non-pharmacologic options alongside or instead of flibanserin, cognitive behavioral therapy (CBT) for HSDD delivered via telehealth has an evidence base (Brotto LA et al., J Sex Med 2008, PMID 18221285). CBT may be covered under Oregon Medicaid mental health benefits without a PA requirement, making it a lower-barrier first-line option for many patients.

Practical Step-by-Step: Getting Flibanserin in Oregon at the Lowest Cost

These concrete steps give Oregon patients a clear path from diagnosis to lowest-cost prescription.

Step 1: Get a proper HSDD diagnosis from a licensed Oregon prescriber. HSDD is defined in DSM-5 as recurrent deficient sexual thoughts and desire causing marked distress for at least 6 months. Self-diagnosis is not sufficient. A telehealth visit with an Oregon-licensed provider costs $49 to $149 and satisfies this requirement.

Step 2: Check your insurance formulary before the prescriber submits a prescription. Call member services, ask for flibanserin (NDC 59630-0580-30) coverage status, tier, and PA requirements. This takes 10 minutes and prevents pharmacy-counter surprises.

Step 3: If commercial insurance covers Addyi, enroll in the Sprout savings card online immediately after the PA is approved. The card can zero out the copay for many plans.

Step 4: If you are on Oregon Medicaid, have your prescriber submit the PA with NAMS guideline citation, DSM-5 criteria documentation, and a note confirming absence of CYP3A4 inhibitors and planned alcohol abstinence. Approval typically takes 3 to 10 business days.

Step 5: If you are uninsured or the copay remains above your budget after the savings card, contact an Oregon-licensed 503A compounding pharmacy for a compounded flibanserin quote. Prices in the $60 to $180 range per month are available. Confirm the pharmacy's Oregon license number before transferring your prescription.

Step 6: After 8 weeks on nightly flibanserin 100 mg at bedtime, complete the FSDS-R questionnaire (freely available via PubMed PMID 11816345) and review with your prescriber. A reduction of 11 or more points on the FSDS-R represents a clinically meaningful response. If you have not reached that threshold, discuss whether continued use is warranted.